Real-World Study Explores Oral Semaglutide Effectiveness in Israeli Type 2 Diabetes Patients

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by high blood sugar, affecting millions globally and leading to severe complications if poorly managed. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide have revolutionized T2DM treatment by improving glycemic control and promoting weight loss. While injectable semaglutide is well-established, the oral formulation offers a convenient alternative, yet its real-world performance in diverse populations, such as in Israel, requires further investigation. This study aims to evaluate the clinical parameters associated with oral semaglutide use in routine Israeli clinical practice, addressing a gap in real-world evidence for this specific demographic.

As this is a study registration record, specific clinical outcomes and quantitative results for this particular study are not yet available. The study, which enrolled 155 adult patients, completed data collection in November 2024, and its findings are anticipated to detail the real-world effectiveness and safety profile of oral semaglutide in managing Type 2 Diabetes within the Israeli healthcare system. Based on existing real-world evidence for oral semaglutide, similar studies typically observe significant improvements in glycemic control and body weight. For instance, an average HbA1c reduction ranging from 1.0% to 1.5% from baseline is commonly reported, with a substantial proportion of patients, often over 60%, achieving an HbA1c below 7.0%. > The most impactful finding in such real-world settings is often a mean body weight reduction of 3-5 kg over 6-12 months, alongside improved cardiovascular risk markers. These studies generally show a favorable safety profile, with gastrointestinal side effects being the most common but usually mild and transient, leading to a low discontinuation rate, typically below 10%, due to adverse events. The real-world setting also allows for observation of adherence rates and overall patient satisfaction, which are crucial for long-term treatment success.